NCT04637204View on ClinicalTrials.gov

Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England

CompletedOBSERVATIONAL

Enrollment

1,540

Participants

Timeline

Start Date

November 24, 2020

Primary Completion Date

December 11, 2020

Study Completion Date

December 11, 2020

Conditions

Renal Cell Carcinoma

Interventions

DRUG

Cabozantinib

oral therapy

DRUG

Axitinib

oral therapy

Trial Locations (1)

Sl1 3XE

Ipsen Facility, Slough

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Ipsen

INDUSTRY